HIV Vaccine: Rosetta Redesign

Margot Kim Image
Tuesday, October 6, 2015
HIV Vaccine: Rosetta Redesign
30 years have passed since the discovery of HIV, and scientists are still struggling to develop a vaccine.

NASHVILLE, Tenn. (KFSN) -- More than 30 years have passed since the discovery of the human immunodeficiency virus, or HIV, and scientists are still struggling to develop a vaccine. But researchers at Vanderbilt University in Nashville have used an unconventional method to get one step closer. Instead of finding an antibody to kill the virus, they simply created one using a computer program.

Four years ago, Josh Robbins was, literally, the poster boy for clinical trials of the HIV vaccine: HVTN 505.

Robbins told Ivanhoe, "I thought I was doing something amazing for the world."

The vaccine was considered a failure. Robbins recorded, and posted on YouTube, the moment he was told he was one of 48 participants who became infected with HIV during the study.

Researchers have now taken a big step forward by finding what amounts to a needle in a haystack.

This computer graphic shows the structure of an antibody, which looks like a ball of string, attached to the HIV protein in green. Using a computer program called "Rosetta", researchers were able to redesign and test it thousands of different ways before finding the one design that made the antibody four times stronger.

Graduate student at Vanderbilt, Jessica Finn, explained, "We could never test a million antibodies in our laboratory, but Rosetta can search through that list of antibodies and pull out candidates."

One reason HIV has been so hard to destroy is because it is always mutating. Director of the Vanderbilt Vaccine Center, James Crowe, MD, said, "So we redesigned this antibody on the computer so that it would kill more viruses."

Researchers say the redesigned antibody will soon become another weapon in the fight against HIV.

Dr. Crowe says within a year, the redesigned antibody will likely be added to current trials as a drug to help people already infected with HIV.

Because of his earlier experience, Robbins continues to advocate the need for volunteers for HIV vaccine trials.

FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT:

Craig Boerner

Vanderbilt Media Relations

Craig.boerner@vanderbilt.edu